Danna Jennings1, Andrew Siderowf2, Matthew Stern2, John Seibyl2, Shirley Eberly2, David Oakes2, Kenneth Marek2. 1. From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Parkinson's Disease and Movement Disorders Center (M.S.), Department of Neurology, University of Pennsylvania, Philadelphia; Department of Biostatistics and Computational Biology (S.E., D.O.), University of Rochester, NY; and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA. djennings@indd.org. 2. From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Parkinson's Disease and Movement Disorders Center (M.S.), Department of Neurology, University of Pennsylvania, Philadelphia; Department of Biostatistics and Computational Biology (S.E., D.O.), University of Rochester, NY; and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA.
Abstract
OBJECTIVES: The purpose of this study is to evaluate the relative risk of abnormal dopamine transporter (DAT) imaging for subjects with and without hyposmia and the feasibility of acquiring a large, community-based, 2-tiered biomarker assessment strategy to detect prodromal Parkinson disease (PD). METHODS: In this observational study, individuals without a diagnosis of PD, recruited through 16 movement disorder clinics, underwent tier 1 assessments (olfactory testing, questionnaires). Tier 2 assessments (neurologic examination, DAT imaging, and other biomarker assessments) were completed by 303 subjects. The main outcome of the study is to compare age-expected [(123)I]β-CIT striatal binding ratio in hyposmic and normosmic subjects. RESULTS: Tier 1 assessments were mailed to 9,398 eligible subjects and returned by 4,999; 669 were hyposmic. Three hundred three subjects (203 hyposmic, 100 normosmic) completed baseline evaluations. DAT deficit was present in 11% of hyposmic subjects compared with 1% of normosmic subjects. Multiple logistic regression demonstrates hyposmia (odds ratio [OR] 12.4; 95% confidence interval [CI] 1.6, 96.1), male sex (OR 5.5; 95% CI 1.7, 17.2), and constipation (OR 4.3; 95% CI 1.6, 11.6) as factors predictive of DAT deficit. Combining multiple factors (hyposmia, male sex, and constipation) increased the percentage of subjects with a DAT deficit to >40%. CONCLUSION: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD. Selecting hyposmic individuals enriches the population for DAT deficit, and combining hyposmia with other potential risk factors (male sex, constipation) increases the percentage of subjects with a DAT deficit compatible with prodromal PD.
OBJECTIVES: The purpose of this study is to evaluate the relative risk of abnormal dopamine transporter (DAT) imaging for subjects with and without hyposmia and the feasibility of acquiring a large, community-based, 2-tiered biomarker assessment strategy to detect prodromal Parkinson disease (PD). METHODS: In this observational study, individuals without a diagnosis of PD, recruited through 16 movement disorder clinics, underwent tier 1 assessments (olfactory testing, questionnaires). Tier 2 assessments (neurologic examination, DAT imaging, and other biomarker assessments) were completed by 303 subjects. The main outcome of the study is to compare age-expected [(123)I]β-CIT striatal binding ratio in hyposmic and normosmic subjects. RESULTS: Tier 1 assessments were mailed to 9,398 eligible subjects and returned by 4,999; 669 were hyposmic. Three hundred three subjects (203 hyposmic, 100 normosmic) completed baseline evaluations. DAT deficit was present in 11% of hyposmic subjects compared with 1% of normosmic subjects. Multiple logistic regression demonstrates hyposmia (odds ratio [OR] 12.4; 95% confidence interval [CI] 1.6, 96.1), male sex (OR 5.5; 95% CI 1.7, 17.2), and constipation (OR 4.3; 95% CI 1.6, 11.6) as factors predictive of DAT deficit. Combining multiple factors (hyposmia, male sex, and constipation) increased the percentage of subjects with a DAT deficit to >40%. CONCLUSION: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD. Selecting hyposmic individuals enriches the population for DAT deficit, and combining hyposmia with other potential risk factors (male sex, constipation) increases the percentage of subjects with a DAT deficit compatible with prodromal PD.
Authors: Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak Journal: Neurobiol Aging Date: 2003 Mar-Apr Impact factor: 4.673
Authors: Bradley F Boeve; Jennifer R Molano; Tanis J Ferman; Siong-Chi Lin; Kevin Bieniek; Maja Tippmann-Peikert; Brendon Boot; Erik K St Louis; David S Knopman; Ronald C Petersen; Michael H Silber Journal: J Clin Sleep Med Date: 2013-05-15 Impact factor: 4.062
Authors: Christopher H van Dyck; John P Seibyl; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; Robert B Innis Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross Journal: Neurology Date: 2001-08-14 Impact factor: 9.910
Authors: Naheed L Khan; Enza Maria Valente; Anna Rita Bentivoglio; Nicholas W Wood; Alberto Albanese; David J Brooks; Paola Piccini Journal: Ann Neurol Date: 2002-12 Impact factor: 10.422
Authors: Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl Journal: Mov Disord Date: 2017-09 Impact factor: 10.338
Authors: Michelle E Fullard; Sharon X Xie; Ken Marek; Matthew Stern; Danna Jennings; Andrew Siderowf; Allison W Willis; Alice S Chen-Plotkin Journal: Mov Disord Date: 2017-09-14 Impact factor: 10.338